drugset / Trial / NCT03052634
A Study of RC48-ADC in Subjects With Advanced Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection in subjects with advanced breast cancer with HER2 positive or HER2 low expression
Timeline
- Start
- 2016-12-23
- Primary completion
- 2022-07-31
- Completion
- 2023-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 1.5 mg/kg | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | — |